ORIGINAL RESEARCH article
Front. Med.
Sec. Rheumatology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1654271
Anti-Porphyromonas gingivalis lipopolysaccharide antibody in rheumatoid arthritis patients with emphysema
Provisionally accepted- 1Tokyo National Hospital (NHO), Tokyo, Japan
- 2Kokuritsu Byoin Kiko Sagamihara Byoin, Sagamihara, Japan
- 3Kokuritsu Byoin Kiko Himeji Iryo Center, Himeji, Japan
- 4Kokuritsu Byoin Kiko Miyakonojo Iryo Center, Miyakonojo, Japan
- 5Kokuritsu Byoin Kiko Nagoya Iryo Center, Nagoya, Japan
- 6Fukushima Kenritsu Ika Daigaku, Fukushima, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid arthritis (RA) as extra-articular manifestations. Anti-Porphyromonas gingivalis (P. gingivalis) antibody (Ab) has been analyzed for the diagnosis of periodontal disease and RA patients showed increased anti-P. gingivalis Ab levels. However, amounts of anti-P. gingivalis Ab in RA complicated with chronic lung disease (CLD) are unknown. We measured anti-P. gingivalis Ab in cases of RA with CLD. Methods: Anti-P. gingivalis lipopolysaccharide (LPS) Ab were measured in RA patient sera by enzyme immunoassay. Results: Anti-P. gingivalis LPS Ab levels in RA with EMP were significantly lower than in RA cases without CLD (P=0.0190, mean ± standard deviation [SD], 32.7 ± 64.2 [×103U/mL] vs. 403.5 ± 2552.7 [×103U/mL]). Multiple logistic regression analyses revealed the independence of this association. Anti-P. gingivalis LPS Ab amounts were increased in RA without CLD (P=0.0412) compared with healthy controls (77.6 ± 183.7 [×103U/mL]). Conclusion: Anti-P. gingivalis LPS Ab levels in RA with EMP were lower compared with RA without CLD. Citrullinated peptides were mainly generated in the lungs of RA with EMP and the oral cavity of RA without CLD, suggesting the heterogeneity of RA.
Keywords: Rheumatoid arthritis, anti-Porphyromonas gingivalis antibodies, Emphysema, chronic lung disease, citrullinated peptides
Received: 26 Jun 2025; Accepted: 04 Sep 2025.
Copyright: © 2025 Oka, Higuchi, Shimada, Fujimori, Hashimoto, Komiya, Saisho, Yoshikawa, Suzuki, Matsui, Fukui, Migita, Tohma and Furukawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hiroshi Furukawa, Tokyo National Hospital (NHO), Tokyo, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.